The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1470
Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
The full article is available to subscribers Subscriber Login   

The FDA has approved nivolumab (Opdivo – BMS), an IV programmed death receptor-1 (PD-1) blocking antibody, for treatment of unresectable or metastatic melanoma that has progressed following treatment with ipilimumab (and a BRAF inhibitor in patients who are BRAF V600 mutation positive) and for treatment of metastatic squamous non-small cell lung cancer (NSCLC) that has progressed on or after platinum-based chemotherapy. It is the second PD-1 inhibitor to be marketed in the US after pembrolizumab (Keytruda),1 and the first to be approved for treatment of NSCLC.

STANDARD TREATMENT — Metastatic melanoma – High-dose interleukin-2 (aldesleukin – Proleukin) has produced responses in 15-20% of patients with metastatic melanoma, but its use has been limited by severe toxicity and cumbersome administration requiring hospitalization for treatment. The ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Nivolumab (Opdivo) for Metastatic Melanoma and Metastatic NSCLC
Article code: 1470b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian